rss
Ann Rheum Dis 2001;60:420-422 doi:10.1136/ard.60.4.420
  • Concise report

Type I collagen degradation does not diminish with RA disease duration

  1. M Hakalaa,
  2. K Ahoc,
  3. S Åmana,
  4. R Luukkainend,
  5. M Kauppia,e,
  6. J Ristelib
  1. aDivision of Rheumatology, Department of Internal Medicine, University of Oulu, Oulu, Finland, bDepartment of Clinical Chemistry, University of Oulu, cNational Public Health Institute, Helsinki, Finland, dDepartment of Rheumatology, Satalinna Hospital, Harjavalta, Finland, eRheumatism Foundation Hospital, Heinola, Finland
  1. Dr M Hakala, Department of Internal Medicine, University of Oulu, FIN-90220 Oulu, Finlandmarkku.hakala{at}oulu.fi
  • Accepted 12 September 2000

Abstract

OBJECTIVE To assess the relation between type I collagen degradation and the duration of rheumatoid arthritis (RA).

METHODS The serum concentrations of cross linked carboxyterminal telopeptide of type I collagen (ICTP) measured earlier in a community based series (90 patients) and a hospital based series (59 patients) were re-evaluated with reference to the duration of RA.

RESULTS The serum ICTP showed a positive correlation with the duration of the disease in the hospital based series (r s=0.40, p<0.01) but not in the community based one (r s=0.18, p=0.10).

CONCLUSIONS Type I collagen degradation predominantly reflecting pathological bone destruction does not seem to diminish in longlasting RA.

Footnotes

    This Article

    1. Abstract
    2. Full text
    3. PDF

    Responses

    1. Submit a response
    2. No responses published

    Register for free content

    The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.

    Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.